Cabazitaxel is a semi-synthetic taxane that stabilises microtubules and overcomes the P-glycoprotein-mediated resistance limiting docetaxel, used for metastatic castration-resistant prostate cancer following prior docetaxel therapy. Simson Pharma's Cabazitaxel reference standard and impurities support stability-indicating method development for this injectable oncology agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cabazitaxel Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.